Findings

What do systematic reviews say?

11 questions · 11 findings · 1 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 27.3%Low 6 · 54.5%Moderate 2 · 18.2%High 0 · 0%

Mycophenolate mofetil vs IV cyclophosphamide

Death · patients with induction therapy in lupus nephritis

It is very uncertain whether mycophenolate mofetil (MMF) changes death compared with IV cyclophosphamide (CPA) (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.12 [0.61, 2.06]
8 studies · 826 participants
Very low

Mycophenolate mofetil vs IV cyclophosphamide

ESKD · patients with induction therapy in lupus nephritis

It is very uncertain whether mycophenolate mofetil (MMF) changes ESKD compared with IV cyclophosphamide (CPA) (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 0.71 [0.27, 1.84]
3 studies · 231 participants
Very low

Mycophenolate mofetil vs IV cyclophosphamide

Complete renal remission · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) showed no clear difference in complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.17 [0.97, 1.42]
8 studies · 828 participants
Low

Mycophenolate mofetil vs IV cyclophosphamide

Partial renal remission · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.02 [0.89, 1.18]
9 studies · 868 participants
Low

Mycophenolate mofetil vs IV cyclophosphamide

Ovarian failure · patients with induction therapy in lupus nephritis

It is very uncertain whether mycophenolate mofetil (MMF) changes ovarian failure compared with IV cyclophosphamide (CPA) (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 0.36 [0.06, 2.18]
3 studies · 539 participants
Very low

Mycophenolate mofetil vs IV cyclophosphamide

Major infection · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) showed no clear difference in major infection compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.02 [0.67, 1.54]
6 studies · 699 participants
Low

Mycophenolate mofetil vs IV cyclophosphamide

Alopecia · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) probably leads to lower alopecia compared with IV cyclophosphamide (CPA) (moderate certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 0.29 [0.19, 0.46]
3 studies · 622 participants
Moderate

Mycophenolate mofetil vs IV cyclophosphamide

Diarrhoea · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) probably leads to higher diarrhoea compared with IV cyclophosphamide (CPA) (moderate certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 2.42 [1.64, 3.58]
4 studies · 609 participants
Moderate

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Partial renal remission · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1 [0.78, 1.28]
2 studies · 402 participants
Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Stable kidney function · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.78 [1.4, 2.26]
2 studies · 402 participants
Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Complete renal remission · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 2.38 [1.07, 5.3]
2 studies · 402 participants
Low